We are pleased to announce that Axcelead Drug Discovery Partners Inc. (“Axcelead”) preparation to become a company independent from Takeda Pharmaceutical Company Limited (“Takeda”) as a core company of “Drug Discovery Gateway Investment Limited Partnership” (“DDG Fund”). Under the terms of the agreement between Takeda and Japan-based Alternative Asset Management Firm, Whiz Partners, Inc. (“Whiz”), DDG Fund will be established by Whiz, and will be launched in November 2018. Takeda will invest Axcelead, in kind into the DDG Fund at the timing of DDG Fund’s launch, and Axcelead will be affiliated with go under the umbrella of DDG Fund.
Takeda News Release
Contact address: email@example.com